Lancet Diabetes & Endocrinology

Papers
(The H4-Index of Lancet Diabetes & Endocrinology is 70. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Direct-to-consumer services: improving access to care for people with diabetes and obesity1198
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale985
South Africa to produce insulin for Africa in 2024655
Reassessing driving safety in diabetes605
Better testing and labelling of drugs for people with obesity604
Anand Hardikar: a scientific nomad searching for the truth442
What's preventing us from curbing the obesity crisis?287
A framework for improving diabetes care in humanitarian emergencies275
Artificial intelligence and diabetes: time for action and caution254
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2248
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98240
Specific cortisol blockade in Cushing's syndrome229
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions225
Type 1 diabetes screening: need for ethical, equity, and health systems perspective208
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p199
Artificial intelligence for interpreting diabetes data using clinician-curated benchmarks198
Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study195
World Health Assembly ratifies first global diabetes targets191
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial182
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?182
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality174
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity173
Clinical features, investigation, and management of Addison's disease170
Implications of technology guidelines for low-income and middle-income countries167
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial162
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial137
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice136
What does renal failure teach us about our National Health System?135
Challenging diabetes stigma starts and ends with all of us130
Glycaemic index as part of the diabetes prevention strategy125
The role of nurses in diabetes care: challenges and opportunities124
A roadmap for integrating mental health and diabetes services122
Cardiovascular mortality trends among people with and without diabetes122
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin115
Healthy weight for the next generation's health in China115
The promise and hope of GLP-1 receptor agonists113
The urgent need for a diabetes data rights charter113
The uncomfortable truth about kidney disease in type 1 diabetes108
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history107
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses103
Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement103
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing102
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply102
Putting wellbeing at the core of diabetes care101
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study99
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials98
Correction to Lancet Diabetes Endocrinol 2025; 13: 935–4896
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study96
Are we closer to surpassing residual renal risk in type 2 diabetes?95
Diabetes and mental health93
Explaining the high rate of progression from prediabetes to type 2 diabetes in China92
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-790
Correction to Lancet Diabetes Endocrinol 2025; published online Nov 19. https://doi.org/10.1016/S2213-8587(25)00289-X89
Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England88
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis87
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial83
3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial81
Understanding the mechanism of prediabetes remission in young people80
CONCEPTT to care: the science of implementation in diabetes care80
The long and winding road to precision diabetology79
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–1778
Bothersome vasomotor symptoms: a potential early clinical marker of perimenopause?78
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international78
Blood pressure control according to type 2 diabetes status77
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–8376
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–1375
Diabetes: knowing your risk matters75
Gender equality: timely and timeless74
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction73
Improving HbA1c levels with advanced hybrid closed-loop therapy71
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors70
Is it time to re-assess the development of thyroid function reference ranges?70
0.11807298660278